AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00792428 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real Transcranial Direct Current Stimulation
Description: A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
Study NCT00792428 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: A sham current runs between two electrode positions and might affect the underlying brain tissue.
Study NCT03938948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser/light therapy
Description: Participants will wear light therapy devices for 14 weeks
Study NCT02674243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodopovidone solution
Description: In this group, iodopovidone solution will be used as pleurodesis substance
Study NCT02674243 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talc
Description: In this group, Talc will be used as pleurodesis substance
Study NCT03672617 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment is given to study participants. Only evaluation of a questionnaire assessing reasons for non-adherence to growth hormone therapy (GHT) and to determine its validity and reliability.~The preliminary working title of the questionnaire GHCQ used in the outcome measures was renamed for simplicity reasons into BAR-GHT (abbreviation for barriers to growth hormone therapy) after study completion.
Study NCT03670173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osalmid
Description: Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year.
Study NCT02388230 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound imaging
Study NCT00870558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ethiodized oil
Description: Given as an intra-arterial infusion
Study NCT00050427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET743
Description: 580 mcg/m2, 3-hour i.v. infusion, on Days 1, 8, and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
Study NCT00050427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET743
Description: 1,300 mcg/m2, 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
Study NCT00206518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere/Docetaxel
Description: Taxotere
Study NCT00206518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin/Cytoxan
Description: Adriamycin/Cytoxan
Study NCT00206518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.
Study NCT03598777 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum Toxin Type A (Dysport) using a vial of 500 U will be injected intramuscularly across pelvic floor muscles.
Study NCT03598777 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Botulinum Toxin Type A (Dysport) using a vial of 500 U will be injected intramuscularly across pelvic floor muscles.
Study NCT03598777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The reconstituted solution will be injected intramuscularly across pelvic floor muscles.
Study NCT02232789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mephedrone
Description: Single oral dose mephedrone
Study NCT02232789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3,4-methylenedioxymethamphetamine
Description: Single oral dose MDMA
Study NCT00870558 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 ethiodized oil
Description: Given as an intra-arterial infusion
Study NCT02232789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oal dose placebo
Study NCT02850614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: gaming application to encourage physical activity
Study NCT02850614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FitBit
Study NCT02850614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Study NCT03032887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: voice prompts
Description: voice prompts on disinfectant dispenser
Study NCT03032887 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: agitation
Description: Education, reminders and optimising materials
Study NCT03032887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: agitation
Description: Education, reminders and optimising materials
Study NCT00003937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT04650646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-related hypoglycaemia
Description: Hypoglycaemia induced by intravenous insulin and exercise on a vertical cycle ergometer.
Study NCT04650646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia under resting conditions
Description: Hypoglycaemia induced by intravenous insulin during bed rest.
Study NCT05271890 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate non-surgical periodontal treatment and oral hygiene instructions
Study NCT02263703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Description: Three 0.5 mL doses will be given at time 0, 2 months after the 1st dose and then 6 months after the initial dose. For kidney transplant recipients the first dose will be at least 6 months post-transplant.
Study NCT02622867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 3547
Description: During one period of parallel study (12 weeks) volunteers consumed 1 capsule/daily with Lactobacillus plantarum 3547 immediately after finishing their meal.
Study NCT02622867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: During one period of parallel study (12 weeks), volunteers will consume 1 daily capsule of maltodextrin immediately after finishing their meal.
Study NCT03253354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive magnetic stimulation
Description: Neurostimulation
Study NCT03253354 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive magnetic stimulation
Description: Neurostimulation
Study NCT00675233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH
Description: Given IV
Study NCT00675233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser therapy
Description: Escalating light doses with 665 nm light
Study NCT02690740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: (diagnostic) conjunctival provocation test with solution: ALK 100, 1.000, 10.000, 20.000, 50.000 and 100.000 SQ-U/ml
Description: see information in arm/group descriptions
Study NCT03873805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
Description: Given IV
Study NCT03873805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03873805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT03873805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01464450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Single 20 mg-dose
Study NCT02596282 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neonatal circumcision under topical anesthesia
Description: The standard procedure for neonatal circumcision is as follows: combined analgesia was topical 2.5% lidocaine and 2.5% prilocaine \<1 gm applied 60 minutes and 40mg acetaminophen suppository 30 minutes prior to surgery. Infants were given a 24% sucrose solution pacifier if needed. Infants under 2 weeks of age received subcutaneous Vitamin K 1 mg. The perineum cleaned, and the penis swabbed with povidone iodine. Hemostats were applied at 3 and 9 o'clock positions and the glans pushed down. Traction was applied before placing the Mogen clamp, the clamp was closed for 5 minutes and the foreskin removed with a scalpel.~Petroleum jelly (e.g., Vaseline) was applied to the glans and the wound covered with sterile gauze. Infants were observed for one hour. Mothers were instructed in wound care.
Study NCT01371565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: mifepristone at doses from 300mg/day up to 1200mg/day
Study NCT00617903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid
Description: 15% foam to be applied topically twice daily
Study NCT00617903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Description: Active-ingredient-free vehicle to be applied topically twice daily
Study NCT04250363 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.
Study NCT04250363 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PfSPZ Challenge
Description: Participants received 3200 units of Plasmodium falciparum sporozoites by DVI on Day 1.
Study NCT04250363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Palcebo
Description: Participants received single oral dose of placebo matched to M5717 capsule on Day 1.
Study NCT04250363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 30 mg
Description: Participants received 30 mg single oral dose of M5717 capsule on Day 1.
Study NCT04250363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 60 mg
Description: Participants received 60 mg single oral dose of M5717 capsule on Day 1.
Study NCT04250363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 80 mg
Description: Participants received 80 mg single oral dose of M5717 capsule on Day 1.
Study NCT02596282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neonatal circumcision under topical anesthesia
Description: The standard procedure for neonatal circumcision is as follows: combined analgesia was topical 2.5% lidocaine and 2.5% prilocaine \<1 gm applied 60 minutes and 40mg acetaminophen suppository 30 minutes prior to surgery. Infants were given a 24% sucrose solution pacifier if needed. Infants under 2 weeks of age received subcutaneous Vitamin K 1 mg. The perineum cleaned, and the penis swabbed with povidone iodine. Hemostats were applied at 3 and 9 o'clock positions and the glans pushed down. Traction was applied before placing the Mogen clamp, the clamp was closed for 5 minutes and the foreskin removed with a scalpel.~Petroleum jelly (e.g., Vaseline) was applied to the glans and the wound covered with sterile gauze. Infants were observed for one hour. Mothers were instructed in wound care.
Study NCT00769483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0646
Description: Starting Dose Level: 5 mg/kg given intravenously over 60 minutes Days 1, 8, 15, 22 of 28 Day Cycle.
Study NCT01759875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir-boosted Atazanavir
Description: Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1
Study NCT01759875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted Atazanavir plus Rabeprazole
Description: Rabeprazole (20mg) PO twice daily (Days 1-3); Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 (Day 4)
Study NCT00769483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 given intravenously over 1-1/2 hours Days 1, 8, and 15 of each 28 Day Cycle.
Study NCT04250363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 100 mg
Description: Participants received 100 mg single oral dose of M5717 capsule on Day 1.
Study NCT04250363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 200 mg
Description: Participants received 200 mg single oral dose of M5717 capsule on Day 1.
Study NCT04250363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants received single oral dose of placebo matched to M5717 capsule on Day 5.
Study NCT04250363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 60 mg
Description: Participants received 60 mg single oral dose of M5717 capsule on Day 5.
Study NCT04250363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 100 mg
Description: Participants received 100 mg single oral dose of M5717 capsule on Day 5.
Study NCT01759875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride
Description: Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 on Day 4
Study NCT01798264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 (exenatide in DUROS)
Study NCT04250363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717 200 mg
Description: Participants received 200 mg single oral dose of M5717 capsule on Day 5.
Study NCT00003937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Study NCT00003937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00769483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100 mg by mouth daily.
Study NCT01012973 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
Description: Intravitreal injection. Weeks 0 to 20 of Aflibercept Injection every 4 weeks; Weeks 24 to 52 every 4 weeks PRN (pro re nata, on demand); plus additional on Week 60 and 68.
Study NCT01012973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham treatment
Description: Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.
Study NCT01012973 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.
Study NCT02321085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus Rhythm control
Study NCT02321085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse Rate control
Study NCT01818700 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Buprenorphine
Description: 8weeks treatment with Norspan®(Buprenorphine)
Study NCT04751175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine, being a non-competitive antagonist of NMDA receptors, could represent a good option as an opioid treatment enhancer for acute postoperative pain and avoid chronic pain, by reducing the '' wind-up '' phenomenon of central sensitization
Study NCT00003937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00003937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT00003937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00563212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aerosol interferon-gamma
Description: aerosol interferon-gamma-1b 100mcg given via nebulizer three times weekly for one year
Study NCT01113476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Starting dose of 50 mg/m\^2 on Day 1, 8 + 15 every 28 days (+/- 2 days)
Study NCT00829894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 1 mg Tablet
Study NCT00829894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 1 mg Tablet
Study NCT01113476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Starting dose of 5 mg/m\^2 on Day 1 + 15 every 28 days (+/- 2 days)
Study NCT01751854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: SSRI alone or with training
Study NCT01751854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo alone or with training
Study NCT02045667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine
Description: Mexiletine is a lidocaine-derivate and belongs to the class of 1B antiarrhythmic agents (Vaughan-Williams Classification of Antiarrhytmica). Class I antiarrhythmics have membrane-stabilizing properties. Drugs in this class work by interfering with the fast influx of sodium by inhibition of sodium ionchannels during the fast depolarization phase, thereby decreasing the maximal voltage and upshoot phase of the action potential.~Mexiletine study-medication will be purchased from Stabilimento Chimico Farmaceutico Militare, Firenze, Italy.
Study NCT02045667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mexiletine
Description: Mexiletine is a lidocaine-derivate and belongs to the class of 1B antiarrhythmic agents (Vaughan-Williams Classification of Antiarrhytmica). Class I antiarrhythmics have membrane-stabilizing properties. Drugs in this class work by interfering with the fast influx of sodium by inhibition of sodium ionchannels during the fast depolarization phase, thereby decreasing the maximal voltage and upshoot phase of the action potential.~Mexiletine study-medication will be purchased from Stabilimento Chimico Farmaceutico Militare, Firenze, Italy.
Study NCT02045667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets do not contain any active medicinal component.
Study NCT02045667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets do not contain any active medicinal component.
Study NCT02794584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sufentanil anesthesia
Description: Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
Study NCT02794584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil anesthesia
Description: Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
Study NCT02794584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid closure
Description: Hybrid closure of ventricular septal defects through the delivery system without cardiopulmonary bypass by transthoracic minimally invasive small incision.
Study NCT02794584 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Surgical closure of ventricular septal defects with cardiopulmonary bypass by routine open thoracotomy.
Study NCT04350697 — intervention group
Intervention type: PROCEDURE
Intervention: Aortic Surgery
Description: Surgery for aortic and/or aortic valve diseases
Study NCT02193022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Study NCT03949296 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Intervention
Description: 10-session program~1. Introduction to mindfulness and its potential benefits~2. Introduction to mindful practices and yoga poses~3. Conditioned reactions to stress; integrating mindfulness into everyday life~4. Challenges and insights gained in practicing mindfulness~5. Using mindfulness to observe and reduce negative means of reacting to stress, and find more effective responses~6. Reacting vs. responding to stressors~7. Self-regulation and coping with stressors and communication challenges~8. Fostering continuity of moment-to-moment awareness while practicing different forms of mindfulness~9. Choosing and creating one's own blend of mindfulness practices~10. Maintaining momentum to practice mindfulness once the program ends
Study NCT00337194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody SGN-30
Description: Given IV
Study NCT00337194 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given IV
Study NCT00337194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV
Study NCT00337194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine tartrate
Description: Given IV
Study NCT00337194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV